AbbVie, Hayman Capital Management cancer news
The Patent Trial and Appeals Board (PTAB) of the U.S. Patent and Trademark Office (PTO) denied an inter partes review (IPR) petition from hedge fund manager Kyle Bass challenging a patent covering AbbVie’s Imbruvica ibrutinib.
The petition challenged U.S. Patent No. 8,754,090, which is one of 12 Orange Book-listed patents covering Imbruvica and expires June 3, 2031. PTAB said the petition did not sufficiently establish that a ClinicalTrials.gov webpage describing a Phase I trial of Imbruvica represented prior art that was available publicly by a specific date, and said the petition’s assertion that the patent was unpatentable due to obviousness relied on the webpage. PTAB also dismissed as moot a motion for sanctions by the patent owner alleging that Bass abused the IPR process. ...